AstraZeneca

Cullgen is a drug discovery service intended to create new drugs for the treatment of diseases that currently lack effective therapies. The company's services use protein degradation technology that focuses on the selective degradation of disease-causing proteins, a novel treatment for cancer, inflammatory and autoimmune diseases, including targets previously considered undruggable, enabling scientists with new means to develop novel therapeutic approaches for various diseases.

Yunjian is a new generation of metabolomics- and protein-based marker-finding technologies. has developed a distinctive analytic platform based on mass spectrometry proteomics and big data, driven by medical theories that greatly reduce the time required by conventional methods to find disease markers. has a wealth of experience in big data illness models, medication development, disease biomarker identification, clinical translation and diagnostics, and data security.

Axbio manufactures next-generation gene sequencing and diagnostic high-end equipment and providing complete industrial solutions.

Yueer is a genomics company driven by technology, with a number of revolutionary molecular detection technologies that can reduce the sequencing cost of all NGS platforms and the sensitivity of qPCR, Sanger, and nanopore sequencing. Yueer Gene collaborates with many partners to develop affordable, timely, and accurate genetic analysis tools in order to achieve precision medicine and improve patient outcomes.

Huma is a global health technology company that provides a modular platform to support digital 'hospitals at home' across different disease areas. Its platform combines predictive algorithms, digital biomarkers, and real-world data to advance proactive, predictive care and research. The company's technology integrates data from hospital databases, patient wearables, and mobile devices to provide real-time information to healthcare providers.

Creativity (Beijing) Medical Technology Development Co., Ltd. is a leading minimally invasive interventional delivery system product full solution provider. Committed to cooperating with top experts at home and abroad in the field of minimally invasive intervention, and cooperating with internationally renowned raw material manufacturers to jointly develop, produce and sell leading products. Provide doctors with differentiated diagnosis and treatment tools, relieve patients' pain and reduce medical burden.

Cellular Biomedicine Group is a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. It is the result of the acquisition, transfer, commercialization, and advancement of thirty years of research and human treatment experience in cellular medicine. Its cellular research and development is the result of collaboration among scientists and doctors from the US, England, and China.

Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.

OnDosis proprietary technology delivers flexible and individualized dosing of oral medicines formulated as micro units. They are focused on providing reassurance in disease management, supporting adherence and providing greater convenience for patients. OnDosis is currently developing products for individualized dosing in diseases with a significant burden on patients and healthcare such as ADHD, pain management and immunosuppression for organ transplants. Hundreds of thousands of patients with these conditions could be helped by improved dosing, ultimately leading to improving health care outcomes. The flexibility of OnDosis technology provides the potential for application across several disease areas and patient segments where conventional tablets or capsules often does not provide a good fit for the patient or treatment goal. OnDosis was founded in 2017 and is headquartered in Gothenburg, Sweden, based on an idea that was spun-out from AstraZeneca, using technology based on development work initiated there. It was founded by GU Ventures and Martin Olovsson. OnDosis operates a network of strategic partners across all core functions including formulation and device development, IP, Regulatory and Business Development.

ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Their ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior therapeutic index compared to first-generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drug candidates for cancer and inflammatory diseases. The Company specializes in the development of novel monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approaches have led to licensing agreements with Novo Nordisk A/S and Bristol-Myers Squibb.

PhaseBio is a clinical-stage biopharmaceutical company committed to developing new and improved drugs, with an initial focus on endocrine and metabolic disorders and cardiovascular disease. The company uses its proprietary recombinant biopolymers called elastin-like polypeptides (ELPs) to improve the stability, bioavailability, activity, and ease of administration of proteins and peptides, with the goal of achieving greater potency, fewer side effects, and better patient compliance. Efficient production in E. coli ensures a low cost of goods. PhaseBio’s lead drug candidate, PB1023, is currently being evaluated in a phase 2b clinical trial for the treatment of hyperglycemia associated with type 2 diabetes, with potential for future use in the treatment of obesity. Our second drug candidate, Vasomera, is currently being evaluated in phase 1 clinical trial and has exciting potential for use in the treatment of pulmonary arterial hypertension (PAH) and heart failure. Its third program, Insumera, basal insulin based on native human insulin, will enter clinical trials in early 2013. PhaseBio is based in Malvern, Pennsylvania.

Viela Bio is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases. The Company’s portfolio selectively targets shared critical pathways that are the root cause of disease. Led by a team of global leaders in inflammation and autoimmunity, Viela Bio strives to be a fully integrated biotechnology company, helping millions of patients worldwide. Viela Bio is located in Gaithersburg, Maryland.

Rani is a clinical-stage biotherapeutics company that enables the development of orally administered biologics to improve patient outcomes. They developed the RaniPill capsule, which is Rani's novel, proprietary, and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The RaniPill capsule is an orally ingestible pill approximately the size of a “000” capsule (or similar to the size of a standard fish oil or calcium pill) that is designed to automatically administer a precise therapeutic dose of medication upon deployment in the small intestine. To date, Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability, and bioavailability using the RaniPill capsule. Their development efforts have enabled them to construct an extensive intellectual property portfolio that they believe provides patients with a competitive advantage.

ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Their ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior therapeutic index compared to first-generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.

Rani is a clinical-stage biotherapeutics company that enables the development of orally administered biologics to improve patient outcomes. They developed the RaniPill capsule, which is Rani's novel, proprietary, and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The RaniPill capsule is an orally ingestible pill approximately the size of a “000” capsule (or similar to the size of a standard fish oil or calcium pill) that is designed to automatically administer a precise therapeutic dose of medication upon deployment in the small intestine. To date, Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability, and bioavailability using the RaniPill capsule. Their development efforts have enabled them to construct an extensive intellectual property portfolio that they believe provides patients with a competitive advantage.

ETHRIS develops mRNA therapeutics with a focus on respiratory diseases and vaccines. ETHRIS possesses an enabling LNP delivery and mRNA modification platform for transcript Therapies. SNIM®RNAis a first-in-class biopharmaceutical which provide a compelling alternative for recombinant protein or gene therapies. SNIM®RNAs encode therapeutic proteins to be produced in the patient‘s body and overcome short duration effects of recombinant proteins. SNIM®RNA Transcript Therapy is a new option for a broad variety of diseases, either acquired or genetically predetermined, lifestyle- or age-related, rare or frequent.

ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Their ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior therapeutic index compared to first-generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.

Moderna Therapeutics is a biotechnology company that develops messenger RNA therapeutics. Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. It provides in vivo drug modality that produces human proteins or antibodies inside patient cells. Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilia, and blood factors, and oncology. Moderna Therapeutics in 2010 and is headquartered in Cambridge in Massachusetts. It has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck.

FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs. The company applies its pioneering expertise in hypoxia-inducible factor (HIF), connective tissue growth factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. FibroGen's product Roxadustat is an oral small-molecule inhibitor of HIF prolyl hydroxylase activity in worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), with a New Drug Application currently under review in China by the State Drug Administration or SDA (formerly the China Food and Drug Administration).

Takeda defined four therapeutic areas of focus: Gastroenterology, Oncology, Central Nervous System, and Cardiovascular and Metabolic.

Acerta Pharma is focused on the development of covalent binding technology solutions to create therapies for cancer. Acerta Pharma was acquired by AstraZeneca in February 2016. Acerta Pharma was founded in 2013 and is based in San Carlos, California.

ZS Pharma is a privately held specialty pharmaceutical company based in Coppell, Texas, and Menlo Park, CA. Its core focus is the research and development of highly selective ion-trap therapies to treat serious medical conditions. The company'ss therapeutic candidate, ZS-9, is a novel treatment for hyperkalemia, a life-threatening condition that affects patients with chronic kidney disease, hypertension, diabetes, and/or chronic heart failure. Hyperkalemia is characterized by abnormally high concentrations of potassium in the blood. ZS-9 is currently being tested in late-stage clinical trials.

ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Their ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior therapeutic index compared to first-generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.

Moderna Therapeutics is a biotechnology company that develops messenger RNA therapeutics. Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. It provides in vivo drug modality that produces human proteins or antibodies inside patient cells. Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilia, and blood factors, and oncology. Moderna Therapeutics in 2010 and is headquartered in Cambridge in Massachusetts. It has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck.

MdBio Foundation, Inc. has been providing innovative and effective bioscience education for middle and high school students since 1997. The non-profit, (501 c 3) organization is dedicated to providing bioscience awareness, education, and workforce development in the state of Maryland and beyond. The Foundation accomplishes this through a diverse set of programs, including their flagship program, MdBioLab, summer programs, and their leading-edge game-based learning platform, MdBioSphere. MdBio Foundation leverages its established, trusted relationships with private industry and school systems to create authentic, STEM-based career experiences on their mobile laboratory, MdBioLab, and through their youth camp, the Young Science Explorers Program (YSEP). These experiences provide a unique opportunity for students to observe first hand the types of careers they could pursue in STEM-related fields. Students and teachers who participate in MdBioLab and YSEP have increased access to information about bioscience industry products, research, and related careers through problem-based laboratory experiences that are aligned with local, state and, national curriculum standards. Commitment to Excellence: Since its inception, The MdBio Foundation has contributed more than $3.5M of their resources to these programs and will continue to invest more than $500K each year. The Foundation’s staff consists of talented and experienced educators and scientists who share a common goal of improving science education and creating a more accessible, educational experience.

Almirall, S.A. is an international pharmaceutical company headquartered in Barcelona, Spain, focused on the research, development, manufacture, and sale of medicines primarily related to skin health. The company offers a range of products for various dermatological conditions, including actinic keratosis, atopic dermatitis, psoriasis, acne, and other diseases, as well as treatments for central nervous system, cardiovascular, and gastrointestinal disorders. Almirall's product portfolio includes well-known medications such as Actikerall, Solaraze, and Ilumetri. To enhance its research capabilities, the company has established collaborations with organizations like Evotec AG, X-Chem, and the University of Dundee, focusing on innovative therapeutics and new drug design. Founded in 1943, Almirall has evolved from its original name, Laboratorios Almirall, to its current designation in 2009, while maintaining a commitment to improving health and well-being through innovation.

UnityPoint Health is a nonprofit health system based in the United States, recognized as one of the country's most integrated healthcare networks. Founded in 1993, it operates more than 280 physician clinics and 30 hospitals across metropolitan and rural areas in Iowa and Illinois. The organization emphasizes coordinated patient care, facilitating communication among healthcare professionals to ensure appropriate treatment settings, whether in clinics, hospitals, or home care. Each year, UnityPoint Health manages over 4 million patient visits, delivering a comprehensive range of services to individuals and families. With annual revenues of $2.7 billion, it ranks as the 13th largest nonprofit health system in the nation and the fourth largest among nondenominational systems.

Elkhorn Logan Valley Public Health Department was created in 2002 to serve the citizens and communities of Burt, Cuming, Madison and Stanton counties. Located in Wisner, Nebraska, with a satellite office in Norfolk, the department focuses on healthy lifestyle management and disease prevention with over 20 programs initiated to maximize wellness and safety.

Established in 1996, Catherine’s Health Center is a 501(c)(3) safety net medical clinic, serving more than 6,000 patients annually. Using a small core of paid staff and many dedicated volunteers, Catherine’s mission is to provide free or low-cost medical services to low-income, uninsured and underinsured residents of Kent Count.Catherine’s Health Center is a non-profit community-based health facility dedicated to serving low-income, uninsured residents of the northeast sections of Grand Rapids, Michigan, primarily those who live in the Creston and Belknap neighborhoods. Supporting the center’s activities are a governing board and group of volunteers working to make health care available to those in need.

Ashland-Boyd County Health Department is located in the Appalachian highlands of eastern Kentucky where the state lines of Kentucky, Ohio and West Virginia meet. Our mission, “To improve the quality of life for all who live, work and play in Boyd County through disease prevention, health promotion, environmental safety and public health preparedness,” is rooted in our long and proud history of serving the residents of our small, yet vibrant community.

Matthew Walker Comprehensive Health Center, Inc. provides healthcare and health education services. It provides pediatric care, family and internal medicine, general dentistry, ophthalmology, geriatrics, obstetrics and gynecology, nutrition, mental health, pharmacy, radiology, and diagnostic laboratory testing and screening services. The company was founded in 1968 and is based in Nashville, Tennessee.

Allegiance Health is a community-owned, locally-governed health system in Jackson, Michigan. We combine hospital-based care with a full range of services for all members of our community. Allegiance is a leader in forming community partnerships which innovatively address wellness and preventative needs. We are proudly entering our 10th decade of serving the people of south central Michigan with local, high-quality care.Comprised of more than 40 different facilities, Allegiance reaches the residents of Jackson, Hillsdale, Lenawee, Ingham, Calhoun and Washtenaw counties and beyond. Wherever we are in the region, our mission remains constant. We lead our community to better health and well-being at every stage of life. Our vision is to create Michigan’s healthiest community through exceptional health care and inspiring a passion for wellness.

North Georgia Healthcare Center is a non-profit health care center in Ringgold, Georgia. NGHCC is federally funded by the U.S.D.A. Direct Loan Program funds. The organization will seek sponsorship through private corporations, community, and grants and it will accept Private Insurance, Medicare, Medicaid. NGHCC will offer medical services to North Georgia and surrounding areas seven days a week with extended hours.

Sankofa Community Development Corporation, founded in 2008, serves as a catalyst to revitalize New Orleans’ Lower and Upper Ninth Ward communities. The nonprofit organization was established to facilitate advances in urban revitalization, healthy living, youth empowerment through education and intergenerational learning. Currently, Sankofa Community Development Corporation leads the Sankofa Mobile Market, Sankofa HEAL Project and Sankofa Learning Gardens and Farms Project.

Whittier Street Health Center (WSHC) is a comprehensive, innovative and high quality health care and wellness center championing equitable access to high quality, cost-effective health care for diverse populations. WSHC is accredited by The Joint Commission (TJC), certified by the NCQA as a golden level (highest ranking) patient centered medical home and licensed by the Massachusetts Department of Public Health (DPH). The vision of the Whittier Street Health Center is to serve as the premiere health center for Boston residents and the mission is to provide high quality, reliable and accessible primary care and support services to promote wellness and eliminate health and social disparities. Located in the Roxbury neighborhood of Boston, Whittier Street Health Center provides comprehensive health services including primary care, behavioral health care, substance abuse services, dental care and eye care to over 25,000 patients. A trusted member of the community for 80 years, Whittier is here to provide the care that you and your family need to get healthy and stay healthy. We provide many services to help raise it out of poverty and into a place of good health. Having translators for 17 languages and utilizing clinical and social services to meet specific community needs through outreach, targeted programs and state of the art health care delivery helps us stay connected with the community.

The Health Wagon is a nonprofit organization providing mobile health services to the medically underserved in southwest Virginia. The Health Wagon’s mission is to provide compassionate, quality healthcare to the medically underserved in the mountains of Appalachia. The Health Wagon visits 10 sites in six counties – Buchanan, Dickenson, Lee, Russell, Scott, and Wise counties – to serve a severely medically underserved population. The Health Wagon currently has two mobile health units and two stationary clinics servicing southwest Virginia.

UCHealth is a not-for-profit healthcare organization founded in 1925 and based in northern Colorado. It serves a broad region that includes Colorado, Nebraska, and Wyoming, covering over 50,000 square miles. The organization operates as a regional medical hub, comprising facilities such as Poudre Valley Hospital, Medical Center of the Rockies, and Mountain Crest Behavioral Health Center, along with numerous clinics and outpatient services. UCHealth is dedicated to providing high-quality, evidence-based care and wellness services, with a mission to improve lives through a combination of academic and community-focused medicine. The organization emphasizes innovation in healthcare while maintaining strong connections with the communities it serves.

Manna Ministries has a longstanding commitment to fiscal responsibility and is audited each year by an independent CPA firm. Our audits reveal that 96% of our funding goes directly to support our programs, while only 4% goes to administrative costs. Partnerships allows us to help more people lead healthier lives by providing them with the basic necessities of life such as food, shelter, and healthcare.

Dr. Arenia C. Mallory Community Health Center (MCHC) is named to honor the memory of Dr. Arenia C. Mallory, well known educator and champion of human causes. She inspired young minds regardless of their race, economic or social status to “Walk in Dignity, Talk in Dignity, and Live in Dignity”.

Based in Wilmington, DE, Christiana Care Health System is one of the largest health care providers in the mid-Atlantic region, serving all of Delaware and parts of Pennsylvania, Maryland and New Jersey. We are a not-for-profit teaching health system that includes two hospitals with more than 1,100 patient beds, a home health care service, preventive medicine, rehabilitation services, a network of primary care physicians and an extensive range of outpatient services. Christiana Care is recognized as a regional center for excellence in cardiology, cancer, orthopaedics and women's health services, as well as for its Level-I trauma care and Level-3 neonatal intensive care (both highest capability).

The Food Trust, a nonprofit founded in 1992, strives to make healthy food available to all. Working with neighborhoods, schools, grocers, farmers and policymakers, we've developed a comprehensive approach that combines nutrition education and greater availability of affordable, healthy food.

Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Pearl Therapeutics is developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases, including chronic obstructive pulmonary disease. Pearl's current focus is on making advanced inhaled therapies available to broad patient populations via familiar and accepted metered dose inhalers. Pearl is a privately held company led by a seasoned team of respiratory product development experts. Pearl aims to offer patients and healthcare providers alternatives that better meet their needs and improve upon the safety and efficacy of existing respiratory therapeutics to achieve better clinical outcomes.

Omthera Pharmaceuticals, Inc. is an emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia. Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease.

Ardea, headquartered in San Diego, California, is a biotechnology company focused on the development,

Guangdong BeiKang Pharmaceutical Company Ltd manufactures drugs which includes generic injectable antibiotics.

Novexel is a pharmaceutical company that researches and develops novel class antiinfectives for the treatment of severe and difficult to treat bacterial and fungal infections. The Company has an extensive portfolio of antibacterial and anti-fungal compounds, R&D programs, and intellectual property. Novexel’s focus is on novel antimicrobial compounds with activity against multi-resistantorganisms. Novexel’s expertise in Biology, Medicinal Chemistry, Pharmacology, Microbiology and Clinical Development positions the Company at the forefront of the discovery and development of novel therapies for infectious disease.

Arrow Therapeutics was founded in 1998 and is already making a significant contribution to anti-infective drug discovery. Microbial resistance to existing drugs is an ever increasing threat that is leading to serious unmet medical need and incurring a huge financial burden on society. Despite the huge challenges of this situation it also presents excellent opportunities to combine scientific research and business. As more and more big pharma groups concentrate their efforts on drug development, greater chances are open to smaller companies such as ours to show their excellence in research.

Cambridge Antibody Technology was a biotechnology company headquartered in Cambridge, England.

KuDOS Pharmaceuticals Ltd discovers and develops drugs based upon the science of DNA damage sensing, signaling, and repair to address medical needs in cancer treatment.